Overview
| Name | Enchant v1/v2 · aliases: Enchant v1, Enchant v2, Enchant v3 |
|---|---|
| Full name | The product name has no expanded form |
| Ambiguous names (not auto-linked) | Enchant |
| Family | Covers three generations of one closed product (v1/v2/v3), none with weights or third-party review
|
| Organization | Iambic Therapeutics |
| Organization type | AI-native biotech |
| Country | United States |
| Model class | Property prediction / multimodal foundation model |
| Domain | Small molecules (also: Text, LLMs & agents, Structure & co-folding) |
| First release | · product update Basis: Company press release for v1 (earliest sourced public evidence) Note: Product-only: no paper and no weights source |
| Other milestones | |
| Latest update | · new version Basis: v3 launch (official page) v3 launched: the company describes a 41B-parameter mixture-of-experts multimodal transformer (v1 1B, v2 7B) taking structures, sequences and omics, tabular assays, physics data, text and images, adding inverse design and peptide capabilities; the parameter framing matches the offering document. The developer's 2026-10-16 listing is a corporate event, not a model update Note: The 41B and mixture-of-experts details were not independently re-verified source The most recent sourced event, not a claim that nothing changed since. |
| Status | Product only, no public artifact · Closed, with no public weights or code; product-only |
| Openness | Code: Closed Weights: Closed All three generations are closed, disclosed only through company pages and press releases, with no weights and no cited API documentation |
| Benchmarks reported | 0 counted (unconfirmed 3) |
| Wet-lab validation | None recorded |
| Unverified fields | † benchmarks_reported[0], benchmarks_reported[1], benchmarks_reported[2], latest_update.description, training_data.b_private_licensed, training_data.c_own_wetlab_for_training |
| As of | 2026-11-16 |
What it does
Puts molecular structures and several experimental and clinically relevant modalities into one transformer, aiming to close the preclinical-to-clinical data gap and predict ADME, pharmacokinetics and clinically relevant endpoints; v2 claims more than a tenfold scale-up over v1 and v3 adds inverse design, omics and image prediction. The company says it fine-tunes weekly across hundreds of molecular properties. TxGemma has been used as a comparator; TerraBind, backed by the same chip investor, instead trains on public data with its own wet-lab validation.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 0 of 3 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 01 CASP | Unconfirmed (not counted) | — | Unconfirmed source | v3 page claims held-out structures from this round, figure only, no protocol; split from a combined candidate and kept unconfirmed. †disputed · evidence |
| 04 TDC (ADMET + DTI) | Unconfirmed (not counted) | — | Unconfirmed source | Obach human PK result not shown to use the TDC split; three site surfaces unified to unconfirmed †disputed · evidence |
| 15 CAMEO | Unconfirmed (not counted) | — | Unconfirmed source | Same source; static 2022 set, figure only. Unconfirmed; would count as retrospective use, not participation. †disputed · evidence |
Other evaluations (outside the 44)
- Public human pharmacokinetics dataset (half-life) (Public benchmark not among the 44) Self-reported: The company reports better correlation than the prior best on the full dataset; the announcement links a baseline page without naming a benchmark and does not state the split
- Low-data setting (Comparison against baselines only) Self-reported: v2 claims that training on 5% of the dataset (about two dozen molecules) beats the prior best trained on all of it
- Company-internal task sets (Own task set) Self-reported: v2 compares against v1 and TxGemma on a kinase set, one company's ADME set, a cell pharmacodynamics set and rat in-vivo clearance, mostly as figures
- v3 protein structure quality comparison (Comparison against baselines only) Self-reported: The official page claims better quality than two public protein models on held-out structures, with figures only and no numbers
Developers report: a multimodal transformer pretrained on abundant preclinical data predicts human pharmacokinetics with very little clinical data and beats the prior best in low-data settings.
Independent evidence: No independent evidence found. The model is closed with no weights and every figure is company-reported; no third-party evaluation or replication was found
Training data
Group in Figure 7: Own wet-lab training data.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Said to come from dozens of external sources, none named; a public human pharmacokinetics dataset is used for the PK task source |
| b. Private or licensed data | Not disclosed | Possibly present but undisclosed; the published site had a claim without scale source |
| c. Own wet-lab data used for training | Yes | Says an in-house automated synthesis and assay platform generates new data continuously, with weekly fine-tuning across dozens of endpoints; scale undisclosed source |
| d. Wet lab used only for validation | Not disclosed |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: An AI small-molecule drug discovery company incorporated in the US in 2019 and renamed in 2023-05, headquartered in California with offices in the UK and Ireland; its offering document reports 171 full-time staff as of 2026-09 (140 R&D, 31 administrative). It runs its own pipeline plus a platform.
- Funding: A $100M Series B in 2023-10 (co-led by two funds, with a chip company and a sequencing company's venture arm as new investors); a $50M extension in 2024-06 (led by sovereign and family capital) taking the round above $150M; a further round of over $100M in 2025-11 with no lead named. The offering document reports about $461.8M raised since inception, $536.5M in total cash and $66.5M of convertible notes converting at listing. The IPO closed 2026-10-16 at $16.00 per share for 9,375,000 shares and $150M.
- Products and partnerships: The pipeline includes an oral brain-penetrant targeted inhibitor (in a phase 1/1b basket trial as of 2026-09), a programme that filed a clinical trial application on 2026-09-30 and one pre-filing programme; the platform comprises this model and a co-folding model. A 2026-09 collaboration and option-to-license deal with a large pharma company covers two initial targets with an upfront, milestones and tiered royalties, terms undisclosed; a 2026-02 research collaboration and licence with another pharma company covers three initial targets with aggregate milestones above $1.7B and $6.2M of revenue recognised in the first half of 2026; five further pharma and compute partners are named.
- Related models: TxGemma, TerraBind, NeuralPLexer3
Reading notes
- Every figure is company-reported and the model is closed, so nothing can be independently reproduced.
- The TDC relation is ruled unconfirmed this round: the blog names no benchmark and no split, and all three published surfaces are unified to unconfirmed.
- The human pharmacokinetics correlation first appeared in the v1 announcement; the v2 blog restates the same figure without saying it was re-run, so it is not a v2 result.
- The real differentiator is continuously generated in-house wet-lab data in training, but its scale has never been disclosed, and v3's parameters and capabilities rest on company statements only.
Caveats
- No counted pairings: all three site relations are unconfirmed.
- Closed, with no weights or code and no third-party review.
- The scale of in-house wet-lab training data is undisclosed.
- Pretraining token and modality counts unique to the press release are not repeated on the official technical page or in the offering document.
Sources
- Official v1 announcement (company blog)
- Official v2 blog (company blog)
- Official v3 page (company blog)
- v1 press release (press)
- Offering document (424B4) (official site)
- Current report on completion of the listing (official site)
Corrections
2 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| benchmarks_reported | TDC self-reported (Chinese matrix and English data) | Unified to unconfirmed and not counted: the blog does not name the benchmark or give the split and protocol | source | 2026-11-16 |
| latest_update | v2 (2025-05-05) as the latest event | 2026-09-21 v3 release; the company listing event is not counted as a model update | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.